A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Exclusion Criteria

• •1. Any significant concomitant medical condition that might interfere with the ability to comply with protocol requirements.
• •2. Has an acute illness within 4 weeks prior to the first dose of study drug which may interfere with study measurements or jeopardize participant's safety.
• •3. Use of the following medications:
• •1. Prior treatment with any exon skipping therapy at any time
• •2. Prior treatment with any gene therapy at any time
• •3. Use of anti-coagulants, anti-thrombotics, or anti-platelet agents
• •4. Use of an immunosuppressants (other than oral corticosteroids for DMD conditions)
• •5. Has taken or is currently taking a histone deacetylase (HDAC) inhibitor, including (but not limited to) givinostat
• •4. Laboratory abnormalities.
• •5. Daytime ventilator dependence or any use of invasive mechanical ventilation via tracheostomy.
• •6. Has an abnormal electrocardiogram (ECG) reading assessed as clinically significant by the investigator, and/or a QT interval with Fridericia correction method (QTcF) \>450 msec at Screening or prior to the first dose of study drug on Day 1.
• •7. Received any experimental or investigational drug, etc. within 3 months prior to first dose or within 5 half-lives (whichever is longer).
• •8. Other protocol-defined criteria apply.